Drug Combination Details
| General Information of the Combination (ID: C41968) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Deferoxamine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| In-vivo Model | The tumor xenograft model was established by subcutaneous inoculation of cultured HL-60 cells (1.0 * 107/ml) in 0.1 ml Hank's balanced salt solution (HBSS) into the right axilla back region of female BALB/c-nu/nu nude mice (3-5weeks of age). | |||||
| Experimental
Result(s) |
Combination of DFO and ATO has synergistic effects on tumor growth inhibition and apoptosis-inducing in vivo with no significant side effects. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The growth-inhibitory and apoptosis-inducing effect of deferoxamine combined with arsenic trioxide on HL-60 xenografts in nude mice. Leuk Res. 2014 Sep;38(9):1085-90. | |||
